Document and Entity Information
Document and Entity Information - shares | 6 Months Ended | |
Jun. 30, 2020 | Aug. 10, 2020 | |
Cover [Abstract] | ||
Entity Registrant Name | Medicine Man Technologies, Inc. | |
Entity Central Index Key | 0001622879 | |
Document Type | 10-Q | |
Document Period End Date | Jun. 30, 2020 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Is Entity's Reporting Status Current? | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Emerging Growth Company | true | |
Entity Small Business | true | |
Entity Shell Company | false | |
Entity Ex Transition Period | false | |
Entity Common Stock, Shares Outstanding | 41,937,146 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2020 | |
Entity Interactive Data Current | Yes | |
Entity Incorporation State Country Code | NV | |
Entity File Number | 000-55450 |
Condensed Balance Sheets (Unaud
Condensed Balance Sheets (Unaudited) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Current assets | ||
Cash and cash equivalents | $ 5,418,317 | $ 11,853,627 |
Accounts receivable, net of allowance for doubtful accounts | 1,291,082 | 313,317 |
Accounts receivable - related party | 124,856 | 72,658 |
Inventory | 1,977,572 | 684,940 |
Notes receivable - related party | 767,695 | 767,695 |
Prepaid expenses and other current assets | 422,000 | 529,416 |
Prepaid acquisition costs (Note 11) | 0 | 1,347,462 |
Total current assets | 10,001,522 | 15,569,115 |
Non-current assets | ||
Fixed assets, net accumulated depreciation of $670,535 and $159,354, respectively | 2,562,612 | 239,078 |
Goodwill | 17,445,843 | 12,304,306 |
Intangible assets, net accumulated amortization of $23,106 and $19,811, respectively | 71,994 | 75,289 |
Investment | 517,514 | 406,774 |
Accounts receivable - litigation | 3,063,968 | 3,063,968 |
Deferred tax assets, net | 268,423 | 268,423 |
Notes receivable - noncurrent, net | 292,101 | 241,711 |
Operating lease right of use assets | 1,747,109 | 59,943 |
Other assets | 41,879 | 0 |
Total non-current assets | 26,011,443 | 16,659,492 |
Total assets | 36,012,965 | 32,228,607 |
Current liabilities | ||
Accounts payable | 2,808,718 | 699,961 |
Accounts payable - related party | 606,196 | 15,372 |
Accrued expenses | 1,848,933 | 1,091,204 |
Derivative liabilities | 1,467,318 | 3,773,382 |
Income taxes payable | 0 | 1,940 |
Total current liabilities | 6,731,165 | 5,581,859 |
Noncurrent liabilities | ||
Lease liabilities | 1,770,742 | 66,803 |
Total noncurrent liabilities | 1,770,742 | 66,803 |
Total liabilities | 8,501,907 | 5,648,662 |
Commitments and Contingencies (Note 10) | 0 | 0 |
Shareholders' equity | ||
Common stock $0.001 par value, 90,000,000 authorized, 42,194,878 shares issued and 41,937,146 shares outstanding at June 30, 2020, and 39,952,628 shares issued and outstanding at December 31, 2019. | 42,195 | 39,953 |
Additional paid-in capital | 59,260,357 | 50,356,469 |
Accumulated deficit | (30,791,494) | (22,816,477) |
Common stock held in treasury, at cost, 257,732 shares held at June 30, 2020 and December 31, 2019. | (1,000,000) | (1,000,000) |
Total shareholders' equity | 27,511,058 | 26,579,945 |
Total liabilities and stockholders' equity | $ 36,012,965 | $ 32,228,607 |
Condensed Balance Sheets (Una_2
Condensed Balance Sheets (Unaudited) (Parenthetical) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Statement of Financial Position [Abstract] | ||
Accumulated depreciation | $ 670,535 | $ 159,354 |
Accumulated amortization | $ 23,106 | $ 19,811 |
Common stock authorized | 90,000,000 | 90,000,000 |
Common stock par value | $ 0.001 | $ 0.001 |
Common stock issued | 42,194,878 | 39,952,628 |
Common stock outstanding | 41,937,146 | 39,952,628 |
Treasury Stock, Common, Shares | 257,732 | 257,732 |
Condensed Statement of Comprehe
Condensed Statement of Comprehensive (Loss) (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Operating revenues | ||||
Total revenue | $ 5,424,329 | $ 1,757,819 | $ 8,627,463 | $ 3,761,295 |
Cost of goods and services | ||||
Cost of goods and services | 3,106,686 | 1,086,413 | 5,255,221 | 2,685,125 |
Total cost of goods and services | 3,106,686 | 1,086,413 | 5,255,221 | 2,685,125 |
Gross profit | 2,317,643 | 671,406 | 3,372,242 | 1,076,170 |
Operating expenses | ||||
Selling, general and administrative expenses | 1,088,479 | 454,389 | 1,755,398 | 823,195 |
Professional services | 2,371,743 | 863,068 | 3,620,731 | 1,633,849 |
Salaries, benefits and related expenses | 2,098,291 | 446,837 | 4,095,327 | 809,058 |
Stock based compensation | 3,109,091 | 2,225,406 | 4,361,822 | 2,980,406 |
Derivative expense - contingent compensation | 0 | 5,024,576 | 0 | 5,400,559 |
Total operating expenses | 8,667,604 | 9,014,276 | 13,833,278 | 11,647,067 |
Income from operations | (6,349,961) | (8,342,870) | (10,461,036) | (10,570,897) |
Other income (expense) | ||||
Gain on forfeiture of contingent consideration | 0 | 0 | 1,462,636 | 0 |
Interest income (expense), net | (11,447) | (192,277) | 36,595 | (192,277) |
Other income (expense) | 32,621 | 0 | 32,621 | 0 |
Unrealized gain (loss) on derivative liabilities | (348,535) | 80,472 | 843,428 | (254,564) |
Unrealized gain (loss) on investment | 81,615 | (367,975) | 110,739 | (716,730) |
Total other income (expense) | (245,746) | (479,780) | 2,486,019 | (1,163,571) |
Net loss | $ (6,595,707) | $ (8,822,650) | $ (7,975,017) | $ (11,734,468) |
Earnings (loss) per share attributable to common shareholders: | ||||
Basic and diluted earnings (loss) per share | $ (0.16) | $ (0.30) | $ (0.20) | $ (0.40) |
Weighted-average number of common shares outstanding - basic and diluted | 41,568,147 | 29,857,473 | 40,742,462 | 29,113,665 |
Other comprehensive income (loss), net of tax | ||||
Total other comprehensive income (loss), net of tax | $ 0 | $ 0 | $ 0 | $ 0 |
Comprehensive income (loss) | (6,595,707) | (8,822,650) | (7,975,017) | (11,734,468) |
Product sales, net [Member] | ||||
Operating revenues | ||||
Total revenue | 4,779,243 | 1,212,499 | 7,197,478 | 2,596,209 |
Product sales - related party, net [Member] | ||||
Operating revenues | ||||
Total revenue | 59,411 | 119,480 | 170,107 | 280,070 |
Consulting and licensing services [Member] | ||||
Operating revenues | ||||
Total revenue | 585,675 | 422,596 | 1,246,932 | 876,265 |
Other Operating Revenues [Member] | ||||
Operating revenues | ||||
Total revenue | $ 0 | $ 3,244 | $ 12,946 | $ 8,751 |
Statement of Changes in Stockho
Statement of Changes in Stockholders' Equity (Unaudited) - USD ($) | Common Stock | Additional Paid-In Capital | Accumulated Deficit | Treasury Stock | Total |
Beginning balance, shares at Dec. 31, 2018 | 27,753,310 | ||||
Beginning balance, value at Dec. 31, 2018 | $ 27,875 | $ 22,886,624 | $ (5,840,735) | $ 17,073,764 | |
Net income (loss) | (11,734,468) | (11,734,468) | |||
Issuance of common stock in connection with sales made under private of public offerings, shares | 2,200,000 | ||||
Issuance of common stock in connection with sales made under private of public offerings, value | $ 2,200 | 4,397,800 | 4,400,000 | ||
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares | 452,426 | ||||
Issuance of common stock in connection with the exercise of common stock purchase warrants, value | $ 451 | 601,273 | 601,724 | ||
Issuance of common stock as compensation to employees, officers and/or directors, shares | 1,190,000 | ||||
Issuance of common stock as compensation to employees, officers and/or directors, value | $ 1,190 | 2,723,710 | 2,724,900 | ||
Issuance of common stock in exchange for consulting, professional, and other services, shares | 173,775 | ||||
Issuance of common stock in exchange for consulting, professional, and other services, value | $ 174 | 305,348 | 305,522 | ||
Stock based compensation expense related to common stock options | 255,506 | 255,506 | |||
Ending balance, shares at Jun. 30, 2019 | 31,769,511 | ||||
Ending balance, value at Jun. 30, 2019 | $ 31,890 | 31,170,261 | (17,575,203) | 13,626,948 | |
Beginning balance, shares at Mar. 31, 2019 | 28,585,098 | ||||
Beginning balance, value at Mar. 31, 2019 | $ 28,705 | 24,071,971 | (8,752,553) | 15,348,123 | |
Net income (loss) | (8,822,650) | (8,822,650) | |||
Issuance of common stock in connection with sales made under private of public offerings, shares | 2,200,000 | ||||
Issuance of common stock in connection with sales made under private of public offerings, value | $ 2,200 | 4,397,800 | 4,400,000 | ||
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares | 334,413 | ||||
Issuance of common stock in connection with the exercise of common stock purchase warrants, value | $ 335 | 444,434 | 444,769 | ||
Issuance of common stock as compensation to employees, officers and/or directors, shares | 476,225 | ||||
Issuance of common stock as compensation to employees, officers and/or directors, value | $ 476 | 1,695,202 | 1,695,678 | ||
Issuance of common stock in exchange for consulting, professional, and other services, shares | 173,775 | ||||
Issuance of common stock in exchange for consulting, professional, and other services, value | $ 174 | 305,348 | 305,522 | ||
Stock based compensation expense related to common stock options | 255,506 | 255,506 | |||
Ending balance, shares at Jun. 30, 2019 | 31,769,511 | ||||
Ending balance, value at Jun. 30, 2019 | $ 31,890 | 31,170,261 | (17,575,203) | 13,626,948 | |
Beginning balance, shares at Dec. 31, 2019 | 39,952,628 | 257,732 | |||
Beginning balance, value at Dec. 31, 2019 | $ 39,953 | 50,356,469 | (22,816,477) | $ (1,000,000) | 26,579,945 |
Net income (loss) | (7,975,017) | (7,975,017) | |||
Issuance of common stock as payment for Mesa, shares | 2,554,750 | ||||
Issuance of common stock as payment for Mesa, value | $ 2,555 | 4,167,253 | 4,169,808 | ||
Return of common stock as compensation to employees, officers and/or directors, shares | (500,000) | ||||
Return of common stock as compensation to employees, officers and/or directors, value | $ (500) | (500) | |||
Issuance of common stock in connection with sales made under private of public offerings, shares | 187,500 | ||||
Issuance of common stock in connection with sales made under private of public offerings, value | $ 187 | 374,813 | 375,000 | ||
Stock based compensation expense related to common stock options | 4,361,822 | 4,361,822 | |||
Ending balance, shares at Jun. 30, 2020 | 42,194,878 | 257,732 | |||
Ending balance, value at Jun. 30, 2020 | $ 42,195 | 59,260,357 | (30,791,494) | $ (1,000,000) | 27,511,058 |
Beginning balance, shares at Mar. 31, 2020 | 39,952,628 | 257,732 | |||
Beginning balance, value at Mar. 31, 2020 | $ 39,953 | 51,609,200 | (24,195,787) | $ (1,000,000) | 26,453,366 |
Net income (loss) | (6,595,707) | (6,595,707) | |||
Issuance of common stock as payment for Mesa, shares | 2,554,750 | ||||
Issuance of common stock as payment for Mesa, value | $ 2,555 | 4,167,253 | 4,169,808 | ||
Return of common stock as compensation to employees, officers and/or directors, shares | (500,000) | ||||
Return of common stock as compensation to employees, officers and/or directors, value | $ (500) | (500) | |||
Issuance of common stock in connection with sales made under private of public offerings, shares | 187,500 | ||||
Issuance of common stock in connection with sales made under private of public offerings, value | $ 187 | 374,813 | 375,000 | ||
Stock based compensation expense related to common stock options | 3,109,091 | 3,109,091 | |||
Ending balance, shares at Jun. 30, 2020 | 42,194,878 | 257,732 | |||
Ending balance, value at Jun. 30, 2020 | $ 42,195 | $ 59,260,357 | $ (30,791,494) | $ (1,000,000) | $ 27,511,058 |
Condensed Statements of Cash Fl
Condensed Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Cash flows from operating activities of continuing operations: | |||
Net income for the period | $ (7,975,017) | $ (11,734,468) | |
Adjustments to reconcile net income to cash used in operating activities: | |||
Depreciation and amortization | 94,269 | 29,042 | |
Common stock issued in exchange for fees and services | 0 | 210,521 | |
Derivative expense | 0 | 5,400,559 | |
Loss on change in derivative liabilities | (2,306,064) | 254,563 | |
Loss on investment, net | (110,739) | 716,730 | |
Stock based compensation | 4,361,822 | 2,980,406 | |
Changes in operating assets and liabilities | |||
Accounts receivable | 780,772 | 775,962 | |
Inventory | 445,345 | (43,844) | |
Prepaid expenses and other assets | 65,538 | (54,279) | |
Operating lease right of use assets and liabilities | 16,773 | (45,226) | |
Accounts payable and other liabilities | 575,153 | 776,684 | |
Income taxes payables | (1,940) | 0 | |
Net cash (used in) operating activities | (4,054,088) | (733,348) | |
Cash flows from investing activities | |||
Purchase of fixed assets, net of sales | (593,785) | (7,312) | |
Purchase of intangible assets | 0 | (6,000) | |
Consideration for acquisition of business | (2,609,500) | 0 | |
Issuance of notes receivable | (50,390) | (229,358) | |
Net cash used in investing activities | (3,253,675) | (242,670) | |
Cash flows from financing activities | |||
Proceeds from issuance of common stock, net of issuance costs and return of common stock | 374,500 | 4,400,000 | |
Proceeds from exercise of common stock purchase warrants, net of issuance costs | 0 | 601,725 | |
Net cash provided by financing activities | 374,500 | 5,001,725 | |
Net decrease in cash and cash equivalents | (6,933,263) | 4,025,707 | |
Cash and cash equivalents - beginning of period | 12,351,580 | 321,788 | $ 321,788 |
Cash and cash equivalents - end of period | $ 5,418,317 | $ 4,347,495 | $ 11,853,627 |
Organization and Nature of Oper
Organization and Nature of Operations | 6 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Business Description | Organization and Nature of Operations Business Description – Business Activity Medicine Man Technologies Inc. (the “Company”) incorporated in Nevada on March 20, 2014. On May 1, 2014, the Company entered into an exclusive technology license agreement with Medicine Man Denver, Inc., f/k/a Medicine Man Production Corporation, a Colorado corporation (“Medicine Man Denver”) whereby Medicine Man Denver granted it a license to use all of their proprietary processes they have developed, implemented and practiced at its cannabis facilities relating to the commercial growth, cultivation, marketing and distribution of medical marijuana and recreational marijuana pursuant to relevant state laws and the right to use and to license such information, including trade secrets, skills and experience (present and future) (the “Medicine Man Denver License Agreement”). The Company commenced its business on May 1, 2014 and generated revenues from consulting activities for prospective clients interested in entering the cannabis industry as well as sponsoring seminars offered to the cannabis industry and other business endeavors related to its core competencies. In 2019, due to the changes in Colorado law permitting outside investment, the Company made a strategic decision to move toward direct plant-touching operations. Following that decision by executive leadership, the Company issued binding term sheets to several Colorado acquisition targets across the value chain. It believes that these targets are high quality, and the Company’s successful acquisition of these potential targets would allow it to become one of the largest vertically integrated seed-to-sale operators in the United States cannabis industry. These term sheets were announced in several Current Reports on Form 8-K during 2019. If successfully completed, the Company, post-transactions, will be able to offer retail, cultivation and extraction services. Management believes that the current company combined with the acquisition targets in its Colorado “roll-up” strategy will have the potential to create a vertically integrated company, which would further enjoy a competitive advantage operating in the Colorado market against incumbent operators. In addition to the contemplated business-integration benefits, management believes the sharing of best practices amongst the Company and the acquisition targets will allow for improved operations, revenue enhancements and increased profitability. Scale may also afford the ability to create an integrated back office system, providing a differentiated technology backbone to support the Company’s operations and enhance its overall management and operating capabilities. There can be no assurance that any of the proposed acquisitions will be consummated. On April 20, 2020, the Company rebranded and conducts its business under the trade name, Schwazze. The corporate name of the Company continues to be Medicine Man Technologies, Inc. Effective April 21, 2020, the Company commenced trading under the OTC ticker symbol SHWZ. On April 20, 2020 the Company completed its first acquisition of a Colorado plant touching entity, acquiring Mesa Organics, Ltd (“Mesa”) and its subsidiaries. These four entities include a Manufacturing Infusing Products (MIP) facility and four dispensaries. All are located in Southeastern Colorado. These acquisitions are included in our Products segment reporting. |
1. Liquidity and Capital Resour
1. Liquidity and Capital Resources | 6 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Liquidity and Capital Resources | 1. Liquidity and Capital Resources During the quarters ending June 30, 2020 and 2019, the Company primarily used revenues from its operation supplemented by cash to fund its operations. Cash and cash equivalents are carried at cost and represent cash on hand, deposits placed with banks or other financial institutions and all highly liquid investments with an original maturity of three months or less as of the purchase date. The Company had $5,418,317 and $11,853,627 classified as cash and cash equivalents as of June 30, 2020, and December 31, 2019, respectively. The Company anticipates it will need additional funds for the Star Buds acquisition and working capital and are exploring capital raising transactions in the form of equity and debt. The Company maintains its cash balances with a high-credit-quality financial institutions. At times, such cash may be more than the insured limit of $250,000. As of June 30, 2020 and December 31, 2019 respectively, the cash balance was $5,168,317 and $486,101 over the insured limit. The Company has not experienced any losses in such accounts, and management believes the Company is not exposed to any significant credit risk on its cash and cash equivalents. The following table depicts the composition of the Company’s cash and cash equivalents as of June 30, 2020, and December 31, 2019: June 30, 2020 December 31, 2019 Deposits placed with banks $ 5,418,317 $ 736,101 United States Treasury Bills – 11,117,526 Total cash and cash equivalents $ 5,418,317 $ 11,853,627 |
2. Critical Accounting Policies
2. Critical Accounting Policies and Estimates | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Critical Accounting Policies and Estimates | 2. Critical Accounting Policies and Estimates Management’s Representation of Interim Financial Statements The accompanying unaudited consolidated financial statements have been prepared by the Company without audit pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”). Certain information and disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) have been condensed or omitted as allowed by such rules and regulations, and management believes that the disclosures are adequate to make the information presented not misleading. These consolidated financial statements include all of the adjustments, which in the opinion of management are necessary to a fair presentation of financial position and results of operations. All such adjustments are of a normal and recurring nature. Interim results are not necessarily indicative of results for a full year. These consolidated financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2019 and 2018, as presented in the Company’s Annual Report on Form 10-K filed on March 30, 2020 with the SEC. Basis of Presentation These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for financial statements. Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates. Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position. Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments include cash, accounts receivable, note receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of each reporting period, using Level 3 inputs. The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis at June 30, 2020 and December 31, 2019, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3): June 30, 2020 December 31, 2019 Level 1 – Marketable Securities Available-for-Sale – Recurring 517,514 406,774 Marketable Securities at Fair Value on a Recurring Basis Certain assets are measured at fair value on a recurring basis. The Level 1 position consists of an investment in equity securities held in Canada House Wellness Group, Inc. (CHV), a publicly-traded company whose securities are actively quoted on the Toronto Stock Exchange. At both June 30, 2020 and December 31, 2019, the Company owned 17,650,540 shares of CHV common stock. The closing share price of CHV’s common stock on June 30, 2020 was CAD$0.040 per share. Fair Value of Financial Instruments The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available-for-sale securities are recorded at current market value as of the date of this report. Accounts Receivable The Company extends unsecured credit to its customers in the ordinary course of business. Accounts receivable related to licensing and consulting revenues are recorded at the time the milestone result in the funds being due being achieved, services are delivered, and payment is reasonably assured. Licensing and consulting revenues are generally collected from 30 to 60 days after the invoice is sent. The following table depicts the composition of our accounts receivable as of June 30, 2020, and December 31, 2019: June 30, 2020 December 31, 2019 Accounts receivable – trade $ 1,332,878 $ 384,202 Accounts receivable – related party 124,856 72,658 Accounts receivable – litigation 3,063,968 3,063,968 Allowance for doubtful accounts (41,796 ) (70,885 ) Total accounts receivable $ 4,479,906 $ 3,449,943 The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required. At June 30, 2020 and December 31, 2019, the Company recorded an allowance for doubtful accounts of $41,796 and $70,885, respectively. During the six months ended June 30, 2020 and June 30, 2019, the Company recorded a bad debt expense of $29,089 and $0, respectively. Notes Receivable On July 17, 2018, the Company entered into an intellectual property license agreement with Abba Medix Corp. (AMC), a wholly owned subsidiary of publicly traded Canada House Wellness Group, Inc. (CHV). The Company agreed to provide a lending facility to AMC in CAD$125,000 increments of up to CAD$500,000. The lending facility is for a term of 36 months and bears interest at a rate of 2%. As of June 30, 2020 and December 31, 2019, the outstanding balance, including accrued interest, on the notes receivable with AMC totaled $292,101 and $241,711, respectively. The Company classified these loans as noncurrent notes receivable on its consolidated balance sheets as of June 30, 2020 and December 31, 2019, respectively. Other Assets (Current and Non-Current) Other assets at June 30, 2020 and December 31, 2019 were $463,879 and $529,416, respectively. As of June 30, 2020, this balance included $422,000 in prepaid expenses and $41,879 in security deposits. At December 31, 2019, other assets included $480,881 in prepaid expenses, $21,085 in interest receivable and $27,450 in security deposits. Prepaid expenses were primarily comprised of insurance premiums, membership dues, conferences and seminars, and other general and administrative costs. Goodwill and Intangible Assets Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of licensing agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from 10 to 15 years. Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test prior to scheduled annual impairment tests. The Company performed its annual fair value assessment at December 31, 2019, on its subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed at June 30, 2020 that would indicate impairment. Long-Lived Assets The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value. The Company evaluated the recoverability of its long-lived assets on December 31, 2019 on its subsidiaries with material amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed at June 30, 2020 that would indicate impairment. Accounts Payable Accounts payable at June 30, 2020 and December 31, 2019 were $2,808,718 and $699,961, respectively and were comprised of trade payables for various purchases and services rendered during the ordinary course of business. Accrued Expenses and Other Liabilities Accrued expenses and other liabilities at June 30, 2020 and December 31, 2019 were $1,848,933 and $1,091,204, respectively. At June 30, 2020, this was comprised of customer deposits of $81,441, accrued payroll of $961,891, and operating expenses of $805,601. At December 31, 2019, accrued expenses and other liabilities was comprised of customer deposits of $148,109, accrued payroll of $714,220, and operating expenses of $228,875. Revenue Recognition and Related Allowances The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) The Company’s revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until the criteria are met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Revenue contracts are identified when accepted from customers and represent a single performance obligation to sell the Company’s products to a customer. The Company has three main revenue streams: product sales; licensing and consulting fees; and other operating revenues from seminars, reimbursements and other miscellaneous sources. Product sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, the Company considers several indicators, including significant risks and rewards of products, its right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers. Revenue from licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved and target harvest yields are exceeded. At June 30, 2020, all milestones for contracts were satisfactorily reached and no further performance obligations were outstanding on contracts through the period. Revenue from seminar fees is related to one-day seminars and is recognized as earned upon the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs. Costs of Goods and Services Sold Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services. General and Administrative Expenses General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services. Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred and totaled $336,529 and $465,796 for the three and six months ended June 30, 2020, respectively, as compared to $73,088 and $128,489, respectively, for the three and six months ended June 30, 2019. Stock Based Compensation Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and Emerging Issues Task Force (“EITF”) 96-18 when stock or options are awarded for previous or current service without further recourse. Share-based expense paid to through direct stock grants is expensed as occurred. Since the Company’s stock has become publicly traded, the value is determined based on the number of shares issued and the trading value of the stock on the date of the transaction. On June 20, 2018, the FASB issued ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements to nonemployees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. Before the amendment, the major difference for the Company (but not limited to) was the determination of measurement date, which generally is the date on which the measurement of equity classified share-based payments becomes fixed. Equity classified share-based payments for employees was fixed at the time of grant. Equity-classified nonemployee share-based payment awards are no longer measured at the earlier of the date which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. They are now measured at the grant date of the award, which is the same as share-based payments for employees. The Company adopted the requirements of the new rule as of January 1, 2019, the effective date of the new guidance. The Company recognized $3,109,091 and $4,361,822 in expense for stock-based compensation from common stock options issued to employees during the three and six months ended June 30, 2020, and $2,225,406 and 2,980,406 in expenses for stock-based compensation from the issuance of common stock to employees, officers, directors and/or contractors during the three and six months ended June 30, 2019. Income Taxes ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Right of Use Assets and Lease Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in determining the present value of lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Operating leases are included in operating lease Right-of-Use assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets. Basic and Diluted Net Income (Loss) Per Share The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share” |
3. Recent Accounting Pronouncem
3. Recent Accounting Pronouncements | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Standards Update and Change in Accounting Principle [Abstract] | |
Recent Accounting Pronouncements | 3. Recent Accounting Pronouncements The Company has implemented all new accounting pronouncements that are in effect and that may impact its financial statements and does not believe that there are any other new pronouncements that have been issued that might have a material impact on its financial position or results of operations except as noted below: FASB ASU 2017-01, Clarifying the Definition of a Business (Topic 805) In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842), |
4. Property and Equipment
4. Property and Equipment | 6 Months Ended |
Jun. 30, 2020 | |
Property, Plant and Equipment [Abstract] | |
Property and Equipment | 4. Property and Equipment Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following: June 30, December 31, Furniture and fixtures $ 129,927 $ 98,903 Leasehold improvements 84,679 40,953 Machinery and tools 1,947,949 34,000 Office equipment 75,848 33,833 Software 110,677 – Work in process 884,067 190,743 $ 3,233,147 $ 398,432 Less: Accumulated depreciation (670,535 ) (159,354 ) Total property and equipment, net of depreciation $ 2,562,612 $ 239,078 Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates. Furniture and fixtures 3 years Leasehold improvements Lesser of the lease term or estimated useful life Machinery and tools 3 years Office equipment 3 years Software 3-5 years Depreciation expense for the three and six months ended June 30, 2020 was $86,510 and $90,974, respectively, compared to $14,966 and $25,617, respectively, for the three and six months ended June 30, 2019. |
5. Intangible Asset
5. Intangible Asset | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible Asset | 5. Intangible Asset Intangible assets at June 30, 2020 and December 31, 2019 were comprised of the following: June 30, December 31, License agreement $ 5,300 $ 5,300 Product license and registration 57,300 57,300 Trade secret – intellectual property 32,500 32,500 Subtotal $ 95,100 $ 95,100 Less: accumulated amortization (23,106 ) (19,811 ) Total intangible assets, net of amortization $ 71,994 $ 75,289 Amortization expense for the three and six months ended June 30, 2020 was $1,647 and $3,295, respectively, compared to $1,729 and $3,425, respectively, for the three and six months ended June 30, 2019. |
6. Derivative Liability
6. Derivative Liability | 6 Months Ended |
Jun. 30, 2020 | |
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |
Derivative Liability | 6. Derivative Liability In 2019, the Company entered into certain employment agreements with key officers that contained contingent consideration provisions based upon the achievement of certain market condition milestones. The Company determined that each of these vesting conditions represented derivative instruments. On January 8, 2019, the Company granted the right to receive 500,000 shares of restricted common stock to an officer and director, which will vest at such time that the Company’s stock price appreciates to $8.00 per share with defined minimum average daily trading volume thresholds. On April 23, 2019, the Company granted the right to receive 1,000,000 shares of restricted common stock to an officer and director, which will vest at such time that the Company’s stock price appreciates to $8.00 per share with defined minimum average daily trading volume thresholds. On February 25, 2020, the director resigned from his remaining positions with the Company and forfeited his right to the contingent consideration. As a result, the Company recorded a gain of $1,462,636 as a component of other income (expense), net on its financial statements. On June 11, 2019, the Company granted the right to receive 1,000,000 shares of restricted common stock to an officer, which will vest at such time that the Company’s stock price appreciates to $8.00 per share with defined minimum average daily trading volume thresholds. The Company accounts for derivative instruments in accordance with the US GAAP accounting guidance under ASC 815, Derivatives and Hedging Activities As of June 30, 2020, the fair value of these derivative liabilities is $1,467,318. The change in the fair value of derivative liabilities for the three months ended June 30, 2020 was $(348,535), resulting in an aggregate unrealized loss on derivative liabilities. The change in the fair value of the derivative liabilities for the six months ended June 30, 2020 was 843,428, resulting in an aggregated unrealized gain on derivative liabilities. |
7. Related Party Transactions
7. Related Party Transactions | 6 Months Ended |
Jun. 30, 2020 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | 7. Related Party Transactions During the year ended December 31, 2019, the Company’s Chief Cultivation Officer, Joshua Haupt, who currently owns 20% of both Super Farm and De Best, was an Officer of the Company and therefore a related party. Effective December 4, 2019, he was no longer an Officer and therefore no longer a related party. As such, he is not included as a related party with respect to sales and accounts receivable to Super Farm or De Best during the period ended June 30, 2020. During the six months ended June 30, 2020, the Company had sales from Medicine Man Denver totaling $170,106. There were no sales discounts during the six months ended June 30, 2020. As of June 30, 2020, the Company had an accounts receivable balance with Medicine Man Denver totaling $83,679. The Company’s former Chief Executive Officer, Andy Williams, maintains an ownership interest in Medicine Man Denver. During the six months ended June 30, 2020, the Company did not record any sales from MedPharm Holdings LLC (“MedPharm Holdings”). As of June 30, 2020, the Company had a net accounts receivable balance with MedPharm Holdings totaling $3,326. Also, during the year ended December 31, 2019, the Company issued various notes receivable to MedPharm Holdings totaling $767,695 with original maturity dates ranging from September 21, 2019 through January 19, 2020 and bearing interest between 8-10% per annum. All notes extended to July 2020 by mutual agreement between the Company and noteholder. The Company’s former Chief Executive Officer, Andy Williams, maintains an ownership interest in MedPharm Holdings. During the six months ended June 30, 2020, the Company did not record any sales from Baseball 18, LLC (“Baseball”), Farm Boy, LLC (“Farm Boy”), Emerald Fields LLC (“Emerald Fields”), or Los Sueños Farms (Los Sueños). During the six months ended June 30, 2020, the Company had a net accounts payable balance of $156,318 with Baseball, $245,953 with Farm Boy, $114,838 with Emerald Fields, and $51,237 with Los Sueños. One of the Company’s former directors, Robert DeGabrielle, owns the Colorado retail marijuana cultivation licenses for Farm Boy, Emerald Fields and Baseball, all doing business as Los Sueños Farms. On May 20, 2020, the Company entered into a second amendment (the “Amendment”) to that certain securities purchase agreement (the “Agreement”) dated as of June 5, 2019 by and between the Company and Dye Capital Cann Holdings, LLC, a Delaware limited liability company (the “Investor” and together with the Company the “Parties”) as described in a Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on June 6, 2019, as amended by the first amendment to the Agreement dated as of July 15, 2019 (the “First Amendment”) and as described in a Current Report on Form 8-K filed with the SEC on July 17, 2019. The Agreement, as amended by the First Amendment, contemplated, among other things, the sale by the Company to the Investor in three separate tranches of shares of the Company’s common stock, par value $0.001 per share (the “Common Stock”), together with warrants to purchase the number of shares of Common Stock purchased in each tranche closing (the “Warrants”). At the time of the closing of the initial transactions contemplated in the Agreement, Justin Dye, principal of the Purchaser, became a Director and Chief Executive Officer of the Company; the Purchaser is currently the Company’s largest shareholder and Mr. Dye has voting and dispositive power over the securities held by the Purchaser. The Amendment provides, pursuant to the terms and subject to the conditions set forth therein, that in addition to the shares of Common Stock and Warrants previously purchased by the Investor in connection with the Agreement as amended by the First Amendment, the Investor shall purchase in a private placement 187,500 shares of Common Stock at a price of $2.00 per share together with 187,500 Warrants at an exercise price of $3.50 per share (the “Transaction”). The Transaction closed on May 21, 2020. |
8. Inventory
8. Inventory | 6 Months Ended |
Jun. 30, 2020 | |
Inventory Disclosure [Abstract] | |
Inventory | 8. Inventory As of June 30, 2020, and December 31, 2019, respectively, the Company had $1,977,572 and $684,940 of inventory. At December 31, 2019 all inventory was finished goods inventory. At June 30, 2020, $849,153 was finished goods inventory and $1,128,419 was raw materials. The Company uses the FIFO inventory valuation method. As of June 30, 2020 and December 31, 2019, the Company did not recognize any impairment for obsolescence within its inventory. |
9. Goodwill
9. Goodwill | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Goodwill | 9. Goodwill On April 20, 2020, the Company closed the acquisition of Mesa Organics, Ltd (“Mesa”). The aggregate purchase price after working capital adjustments was $2,609,500 of cash and 2,554,750 shares of the Company’s common stock, par value $0.001 per share. The Company accounted for the transaction utilizing purchase price accounting stating that the book value approximates the fair market value of the assets acquired. The purchase price accounting resulted in the Company valuing the investment as $5,141,537 of goodwill. The purchase price allocation is preliminary. The purchase price allocation will continue to be preliminary until a third-party valuation is finalized and the fair value and useful life of the assets acquired is determined. The amounts from the final valuation may significantly differ from the preliminary allocation. The following table sets forth the changes in the carrying value of the Company’s goodwill at June 30, 2020 and December 31, 2019: Balance, December 31, 2019 $ 12,304,306 Acquisition of Mesa 5,141,537 Balance, June 30, 2020 $ 17,445,843 |
10-. Leases
10-. Leases | 6 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Leases | 10. Leases Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. Leases with a term greater than one year are recognized on the balance sheet at the time of lease commencement or modification of a right of use (“ROU”) operating lease asset and a lease liability, initially measured at the present value of the lease payments. Lease costs are recognized in the income statement over the lease term on a straight-line basis. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. The Company's leases consist of real estate leases for office, commercial retail, and storage spaces. The Company elected to combine the lease and related non-lease components for its operating leases. The Company’s operating leases include options to extend or terminate the lease, which are not included in the determination of the ROU asset or lease liability unless reasonably certain to be exercised. The Company's operating leases have remaining lease terms of three to five years. The Company’s lease agreements do not contain any material residual value guarantees or material restrictive covenants. As the Company's leases do not provide an implicit rate, we used an incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The discount rate used in the computation is 6%. Balance Sheet Classification of Operating Lease Assets and Liabilities Balance Sheet Line June 30, 2020 Asset Operating lease right of use assets Noncurrent assets $ 1,747,109 Liabilities Lease liabilities Noncurrent liabilities $ 1,770,742 Lease Costs The table below summarizes the components of lease costs for the six months ended June 30, 2020. Six Months Ended Operating lease costs $ 101,568 Maturities of Lease Liabilities Maturities of lease liabilities as of June 30, 2020 are as follows: 2020 fiscal year $ 1,793,866 Less: Interest (23,124 ) Present value of lease liabilities $ 1,770,742 The following table presents the Company’s future minimum lease obligation under ASC 840 as of June 30, 2020: 2020 fiscal year $ 225,732 2021 fiscal year 451,464 2022 fiscal year 451,464 2023 fiscal year 410,232 2024 fiscal year 369,000 2025 fiscal year 123,000 Total $ 2,030,892 |
11. Commitments and Contingenci
11. Commitments and Contingencies | 6 Months Ended |
Jun. 30, 2020 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | 11. Commitments and Contingencies Binding Term Sheets to Acquire Certain Businesses Over the past three years, the Company has supported legislation in Colorado to allow licensed cannabis companies in Colorado to trade their securities, provided they are reporting companies under the Exchange Act, as amended. HB19-1090 titled, “Publicly Licensed Marijuana Companies” was signed into law on May 29, 2019 and went into effect on November 1, 2019. The bill repeals the provision that prohibits publicly traded corporations from holding a marijuana license in Colorado. Effective January 10, 2019, the Company entered into binding term sheets to acquire three cannabis and cannabis related companies, including the following: · FutureVision 2020, LLC and FutureVision Ltd., Inc. dba Medicine Man Denver (in the aggregate, “Medicine Man Denver”), owners of several licensed dispensaries and a cultivation facility in the Denver, Colorado metro area. It is also a leading cultivator, retailer and one of the best-known brands in the cannabis sector, winning over a dozen industry awards. Medicine Man Denver operates out of a 35,000 square foot cultivation operation and has four popular retail locations across the Denver metropolitan area. This term sheet expires on August 31, 2020 and the Company communicated it was terminating the term sheet on Friday, August 14, 2020; · MedPharm Holdings, a company that develops and manages intellectual property related to the manufacture and formulation of products containing cannabinoid extracts. Management believes that this acquisition will bring world-class processing and pharmaceutical-grade products to the company; and · MX LLC, the holder of the license that allow it to be a manufacturer of marijuana infused products in the Denver metro area. It also has a research license that has been issued by the state of Colorado and the local jurisdiction approval is in process. The term sheets provide for the issuance of shares of common stock to the targets at an initial price per share of $1.32, with the final price to be determined based on the fair market valuation, which is subject to an independent valuation assessment. The Company’s former Chief Executive Officer, Andrew Williams, serves as an officer/manager and has an ownership interest in each of the targets above. On August 15, 2019, the Company entered into a binding term sheet with Medically Correct, LLC (“Medically Correct”), an edible, extract and topical company, setting forth the terms of the acquisition by the Company of 100% of the capital stock and assets of Medically Correct. As consideration, the Company shall pay a total purchase price of $17,250,000 consisting of $3,450,000 cash and 4,677,967 shares of its common stock, par value $0.001 per share. The 4,677,967 shares were determined by averaging the closing price of Company’s common stock for the five (5) days prior to August 8, 2019. On September 5, 2019, the Company entered into a binding term sheet dated September 2, 2019 with RSFCG, LLC, RFSCA LLC, RFSCB, LLC, RFSCEV, LLC, RFSCED LLC, RFSCLV, LLC, RFSCG-1 LLC, and RFSCLVG LLC, which entities operate under the name Roots RX (“Roots RX”) pursuant to which the Company will purchase the membership interests of Roots RX. As consideration, the Company shall pay a total purchase price of $15,000,000 consisting of $9,750,000 in cash and 1,779,661 shares of its common stock, par value $0.001 per share. The 1,779,661 shares were determined by averaging the closing price of Company’s common stock for the five (5) days prior to August 29, 2019. On September 9, 2019, the Company entered into a binding term sheet with Canyon, LLC (“Canyon”) and It Brand Enterprises, LLC (“It Brand”) pursuant to which the Company will purchase 100% of the capital stock or assets of Canyon and certain assets of It Brand. As consideration, the Company shall pay a total purchase price of $5,130,000 consisting of (i) a cash component which in no case will be greater than $2,565,000, and (ii) an equity component, which will consist of shares of the Company’s common stock, par value $0.001 per share, for the balance of the purchase price. The number of shares that make up the equity component will be determined by dividing the balance of the Purchase Price by the average closing price of Company’s common stock for the five (5) days prior to September 7, 2019. Definitive Agreement to Acquire the Colorado-Based Star Buds Branded Dispensaries On June 5, 2020, the Company and SBUD, LLC, a Colorado limited liability company and wholly owned subsidiary of the Company (the “Purchaser”) entered into thirteen separate purchase agreements (each individually the “CHC Agreement” the “Citi Agreement” the “Lucky Agreement” the “Kew Agreement” the “Aurora Agreement” the “Arapahoe Agreement” the “Alameda Agreement” the “44th Agreement” the “Pueblo Agreement” the “Louisville Agreement” the “Niwot Agreement” the “Longmont Agreement” and the “Commerce City Agreement,” and collectively the “Agreements”) together with each of Colorado Health Consultants, LLC, CitiMed, LLC, Lucky Ticket LLC, Kew LLC, SB Aurora LLC, SB Arapahoe LLC, SB Alameda LLC, SB 44th LLC, Star Buds Pueblo LLC, Star Buds Louisville LLC, Star Buds Niwot LLC, Star Buds Longmont LLC, and Star Buds Commerce City LLC (any one a “Star Buds Company” and collectively the “Star Buds Group”) whereby the Purchaser agreed to purchase substantially all of the assets of the Star Buds Group from each individual Star Buds Company pursuant to the Agreements (the “Purchase”). As previously disclosed in a Current Report on Form 8-K filed September 3, 2019, the Company and the Star Buds Group entered into a binding term sheet whereby the Company agreed to purchase the membership interests of each member of each Star Buds Company (the “Proposed Transaction”); the Agreements were entered into in lieu of the Proposed Transaction. The aggregate purchase price for the assets of the Star Buds Group is approximately $118 million, subject to adjustment upon the closing of the Purchase based on, among other things, the target inventory as opposed to actual inventory and target working capital as opposed to net working capital of each member of the Star Buds Group, and shall be payable to the Star Buds Group and the members a mix of cash and shares of the Company’s common stock, par value $0.001 per share (the “Purchase Price”). The Purchaser will not assume any liabilities of the Star Buds Group other than accounts payable by Star Buds Group, liabilities in respect of any contractual arrangements assigned to the Purchaser by the Star Buds Group, and liabilities in connection with administrative fees associated with obtaining necessary governmental approvals or waivers of such approvals. The Purchaser has also agreed to pay certain transfer taxes in connection with the Purchase. The closing of the Purchase is subject to customary closing terms and conditions, and the closing of the purchase of the assets by the Purchaser of any Star Buds Company is subject to additional closing conditions as set forth in the Agreements. Prepaid acquisition costs The Company has entered into a number of sales transactions with companies above for which it has executed binding term sheets to acquire. The Company expects to settle each of these outstanding balances with the respective entity at the time of, or shortly following, their acquisition. The contemplated acquisitions detailed above are conditioned upon the satisfaction or mutual waiver of certain closing conditions, including, but not limited to: · regulatory approval relating to all applicable filings and expiration or early termination of any applicable waiting periods; · regulatory approval of the Marijuana Enforcement Division and applicable local licensing authority approval; · receipt of all material necessary, third party, consents and approvals; · each party's compliance in all material respects with the respective obligations under the term sheet; · a tax structure that is satisfactory to both the Company and the targets; · the execution of leases and employment agreements that are mutually acceptable to each party; and · the execution of definitive agreements between the respective parties. There can be no assurance that the Company will be able to consummate any of the proposed acquisitions. Departure of Officers On February 25, 2020, Andy Williams resigned from the positions of President and member of the Board of Directors of the Company. Mr. Williams’s resignation was not the result of any disagreement with the Company on any matter relating to the company’s operations, policies or practices. Simultaneously, the Company entered into a Severance Agreement and Release (the “Severance Agreement”) with Mr. Williams. The Severance Agreement provides that as severance and in consideration of a customary release against the Company and other customary covenants, Mr. Williams will receive (i) continued salary in the amount of $300,000, half of which to be paid within ten days of the execution of the Severance Agreement, and the remaining half is to be paid in 26 equal disbursements in accordance with the Company’s regular payroll periods, (ii) bonus payment in the amount of $25,000, (iii) one year family health care coverage, (iv) stock options to purchase 350,000 shares of the Company’s common stock, which may be exercised on a cashless basis and which vest immediately on the date of termination at a price of $1.80 per share and valued at $582,228, and (v) stock options to purchase 15,000 shares of the Company’s common stock, which may be exercised on a cashless basis at a price of $1.80 per share, valued at $27,000, at the one year anniversary of the termination date if Mr. Williams is compliant with the terms of the Severance Agreement. On June 19, 2020, the Company received the resignation of Robert DeGabrielle from the positions of Chief Operating Officer and member of the Board of Directors of the Company. Mr. DeGabrielle’s resignation was not the result of any disagreement with the Company on any matters relating to the Company’s operations, policies, or practices. |
12. Stockholders' Equity
12. Stockholders' Equity | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Stockholders' Equity | 12. Stockholders’ Equity On December 10, 2019, the shareholders approved an amendment to the Company’s articles of incorporation increasing the number of authorized shares of common stock from 90,000,000 shares to 250,000,000 shares. The Company is authorized to issue two classes of shares, designated preferred stock and common stock. Preferred Stock The number of shares of preferred stock authorized is 10,000,000, par value $0.001 per share. The preferred stock may be divided into such number of series as the Company’s Board of Directors may determine. The Board is authorized to determine and alter the rights, preferences, privileges and restrictions granted and imposed upon any wholly unissued series of preferred stock, and to fix the number and designation of shares of any series of preferred stock. The Board, within limits and restrictions stated in any resolution of the Board, originally fixing the number of shares constituting any series may increase or decrease, but not below the number of such series then outstanding, the shares of any subsequent series. Common Stock The Company is authorized to issue 250,000,000 shares of common stock at a par value of $0.001 and had 42,194,878 shares of common stock issued and 41,937,146 shares of common stock outstanding as of June 30, 2020, and 39,952,628 shares of common stock issued and outstanding as of December 31, 2019. Common Stock Issued in Connection with the Exercise of Warrants During the six months ended June 30, 2019, the Company issued 452,426 shares of common stock for proceeds of $601,725 under a series of stock warrant exercises with an exercise price of $1.33 per share. During the six months ended June 30, 2020, the Company issued 187,500 shares of common stock for proceeds of $375,000 under a series of stock warrant exercises with an exercise price of $2.00 per share. Common Stock Issued as Compensation to Employees, Officers, Directors and Contractors On January 8, 2019, the Company granted to an officer of the Company, Paul Dickman, 500,000 shares of common stock, valued at $660,000. On March 14, 2019, the Company granted 50,000 shares of common stock to James Toreson upon his resignation as a member of its board of directors for his service. These shares were valued at $95,000. Concurrent with his resignation, the Company issued 50,000 shares of its common stock to Mr. Toreson in connection with a consulting agreement having a service period extending through May 31, 2020. These shares were valued at $95,000. On April 3, 2020, the Company cancelled 500,000 shares of common stock, with vesting conditions represented as derivative instruments. These shares were incorrectly issued as restricted shares instead of restricted stock units to an officer of the Company, Paul Dickman, on January 8, 2019. The return of these shares had no impact on EPS for the quarter ended June 30, 2020. Common Stock Issued as Payment for Acquisition On April 20, 2020, the Company issued 2,554,750 shares of common stock valued at $4,167,253 for the acquisition of Mesa Organics, Ltd. Warrants The Company accounts for common stock purchase warrants in accordance with ASC 480, Accounting for Derivative Financial Instruments Indexed to, and Potentially Settled in, a Company’s Own Stock, Distinguishing Liabilities from Equity During the year ended December 31, 2019, the Company issued 9,800,000 common stock purchase warrants to various accredited investors with an exercise price of $3.50 per share with an expiration date of three years from the date of issuance. On May 20, 2020, the Company issued an additional 187,500 common stock purchase warrants with an exercise price of $3.50 per share with an expiration date of three years from the date of issuance. The Company estimated the fair value of these warrants at date of grant using the Black-Scholes option pricing model using the following inputs: (i) stock price on the date of grant of $3.50, (ii) the contractual term of the warrant of 3 years, (iii) a risk-free interest rate ranging between 0.21% - 1.84% and (iv) an expected volatility of the price of the underlying common stock ranging between 158% - 173%. The following table reflects the change in common stock purchase warrants for the six months ended June 30, 2020. All stock warrants are exercisable for a period of three years from the date of issuance. Number of shares Balance as of January 1, 2020 9,800,000 Warrants exercised – Warrants forfeited – Warrants issued 187,500 Balance as of June 30, 2020 9,987,500 |
13. Segment Information
13. Segment Information | 6 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Segment Information | 13. Segment Information The Company has three identifiable segments as of June 30, 2020; (i) products, (ii) consulting and licensing and (iii) corporate, infrastructure and other. The products segment sells merchandise directly to customers via e-commerce portals, through the Company’s proprietary websites and retail location. The licensing and consulting segment sales derives its revenue from licensing and consulting agreements with cannabis related entities, in addition to fees from seminars and expense reimbursements included in other revenue on the Company’s financial statements. The corporate, infrastructure and other segment represents new resources added in anticipation of various acquisition transactions and other corporate related costs. The following information represents segment activity for the three-month periods ended June 30, 2020 and June 30, 2019: For the Three Months Ended For the Three Months Ended 30-June-2020 30-June-2019 Products Consulting and Licensing Corporate, Infrastructure and Other Total Products Consulting and Licensing Corporate, Infrastructure and Other Total Revenues $ 4,838,654 $ 585,675 $ – $ 5,424,329 $ 1,301,735 $ 456,084 $ – $ 1,757,819 Cost of goods and services $ (2,833,244 ) $ (273,442 ) $ – $ (3,106,686 ) $ (319,229 ) $ (767,184 ) $ – $ (1,086,412 ) Gross profit $ 2,005,410 $ 312,233 $ – $ 2,317,643 $ 982,506 $ (311,100 ) $ – $ 671,406 Intangible assets amortization $ 1,514 $ 133 $ – $ 1,647 $ 1,597 $ 132 $ – $ 1,729 Depreciation $ 79,809 $ 6,701 $ – $ 86,510 $ 1,700 $ 13,266 $ – $ 14,966 Income (loss) from operations $ 925,258 $ 313,028 $ (7,833,993 ) $ (6,595,707 ) $ 237,239 $ (197,465 ) $ (8,862,424 ) $ (8,822,650 ) Segment assets $ 9,578,911 $ (6,240,425 ) $ 2,645,188 $ 5,983,674 $ 222,826 $ (9,269,203 ) $ 12,646,902 $ 3,600,525 The following information represents segment activity for the six-month periods ended June 30, 2020 and June 30, 2019: For the Six Months Ended For the Six Months Ended 30-June-20 30-June-19 Products License/Cons. Corporate Infrastructure and Other Total Products License/Cons. Corporate Infrastructure and Other Total Revenues 7,367,585 1,259,878 – 8,627,463 2,880,042 881,253 – 3,761,295 COGS (4,729,470 ) (525,751 ) – (5,255,221 ) (1,729,670 ) (955,455 ) – (2,685,125 ) Gross profit 2,638,115 734,127 3,372,242 1,150,372 (74,202 ) – 1,076,170 Intangible assets amortization 3,027 268 – 3,295 3,160 265 – 3,425 Depreciation 81,041 9,933 – 90,974 3,400 22,217 – 25,617 Income (loss) from operations 1,371,757 467,455 (9,814,229 ) (7,975,017 ) 179,552 (394,681 ) (11,519,339) (11,734,468 ) Segment assets 22,513,985 247,170 13,251,810 36,012,965 5,435,508 287,359 15,642,009 21,364,876 |
14. Tax Provision
14. Tax Provision | 6 Months Ended |
Jun. 30, 2020 | |
Income Tax Disclosure [Abstract] | |
Tax Provision | 14. Tax Provision The company utilizes FASB ASC 740, Income Taxes The Company recorded no tax provision as of June 30, 2020. As of June 30, 2020, the Company had federal, state and local net operating loss carryforwards of approximately $10.2 million that are available to offset future liabilities for income taxes. The Company has generally established a valuation allowance against these carryforwards based on an assessment that it is more likely than not that these benefits will not be realized in future years. The federal and state net operating loss carryforwards expire in 2039. |
15. Subsequent Events
15. Subsequent Events | 6 Months Ended |
Jun. 30, 2020 | |
Subsequent Events [Abstract] | |
Subsequent Events | 15. Subsequent Events In accordance with FASB ASC 855-10, Subsequent Events Termination of Proposed Acquisitions On July 1, 2020, the Company terminated the binding term sheet (the “Dabble Term Sheet”) with Cold Baked, LLC and Golden Works, LLC (d/b/a “Dabble”), each a Colorado limited liability company, which term sheet had set forth the terms of the acquisition by the Company of 100% of the capital stock and assets of Dabble. The Dabble Term Sheet was previously described in the Company’s Current Report on Form 8-K filed on August 12, 2019, and incorporated herein by reference. On July 1, 2020, the Company terminated the binding term sheet (the “Los Suenos Term Sheet”) with Los Suenos, LLC (“Los Suenos”) and Emerald Fields Grow, LLC (“Emerald”), each a Colorado limited liability company, which term sheet had set forth the terms of the acquisition by the Company of 100% of the capital stock and assets of Los Suenos and Emerald, respectively. The Los Suenos Term Sheet was previously described in the Company’s Current Report on Form 8-K filed on June 6, 2019, and incorporated herein by reference. On July 1, 2020, the Company terminated the binding term sheet (the “Farm Boy Term Sheet”) with Farm Boy, LLC (“Farm Boy”) and Baseball 18, LLC (“Baseball”), each a Colorado limited liability company, which term sheet had set forth the terms of the acquisition by the Company of 100% of the capital stock and assets of Farm Boy and Baseball, respectively. The Farm Boy Term Sheet was previously described in the Company’s Current Report on Form 8-K filed on June 6, 2019, and incorporated herein by reference. On July 27, 2020, the Company received notice of termination from Medically Correct, LLC (“MC”) terminating the term sheet to acquire MC. The term sheet was previously described in the Company’s Current Report on Form 8-K filed on August 20, 2019, and incorporated herein by reference. On August 14, 2020 the Company terminated the term sheet with FutureVision 2020, LLC and FutureVision Ltd., Inc. dba Medicine Man Denver (in the aggregate, “Medicine Man Denver”), owners of several licensed dispensaries and a cultivation facility in the Denver, Colorado metro area. But for the termination on August 14, 2020, the Medicine Man Denver term sheet would have expired on August 31, 2020. Note Receivable On August 1, 2020, the Company entered into a Settlement Agreement and Mutual Release (“Settlement Agreement”) with MedPharm Holdings, Inc. The Parties agreed that the amount of the settlement is $767,695 in principal and $47,161 in accrued interest, thru July 31, 2020. The Company received a $100,000 payment from MedPharm, which was to be paid by August 1, 2020. In addition to the immediate $100,000 principal payment, Andrew Williams, a member of the MedPharm Board of Directors, will deliver and transfer to Schwazze 175,000 shares of Schwazze common stock as equity consideration by August 15, 2020 at a price of $1.90 per share. The remaining outstanding receivable will be paid out in bi-weekly installments of product by scheduled deliveries through March 31, 2021. |
2. Critical Accounting Polici_2
2. Critical Accounting Policies and Estimates (Policies) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Basis of Presentation | Basis of Presentation These accompanying financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) and pursuant to the rules and regulations of the Securities and Exchange Commission for financial statements. |
Use of Estimates | Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported therein. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be based upon amounts that differ from these estimates. |
Reclassifications | Reclassifications Certain prior period amounts have been reclassified to conform to the current period presentation. These reclassifications had no impact on net earnings and financial position. |
Fair Value Measurements | Fair Value Measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability, in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy is based on three levels of inputs, of which the first two are considered observable and the last unobservable, as follows: Level 1 – Quoted prices in active markets for identical assets or liabilities. Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. The Company’s financial instruments include cash, accounts receivable, note receivable, accounts payables and tenant deposits. The carrying values of these financial instruments approximate their fair value due to their short maturities. The carrying amount of the Company’s debt approximates fair value because the interest rates on these instruments approximate the interest rate on debt with similar terms available to us. The Company’s derivative liability was adjusted to fair market value at the end of each reporting period, using Level 3 inputs. The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis at June 30, 2020 and December 31, 2019, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3): June 30, 2020 December 31, 2019 Level 1 – Marketable Securities Available-for-Sale – Recurring 517,514 406,774 |
Marketable Securities at Fair Value on a Recurring Basis | Marketable Securities at Fair Value on a Recurring Basis Certain assets are measured at fair value on a recurring basis. The Level 1 position consists of an investment in equity securities held in Canada House Wellness Group, Inc. (CHV), a publicly-traded company whose securities are actively quoted on the Toronto Stock Exchange. At both June 30, 2020 and December 31, 2019, the Company owned 17,650,540 shares of CHV common stock. The closing share price of CHV’s common stock on June 30, 2020 was CAD$0.040 per share. |
Fair Value of Financial Instruments | Fair Value of Financial Instruments The carrying amounts of cash and current assets and liabilities approximate fair value because of the short-term maturity of these items. These fair value estimates are subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. Changes in assumptions could significantly affect these estimates. Available-for-sale securities are recorded at current market value as of the date of this report. |
Accounts receivable | Accounts Receivable The Company extends unsecured credit to its customers in the ordinary course of business. Accounts receivable related to licensing and consulting revenues are recorded at the time the milestone result in the funds being due being achieved, services are delivered, and payment is reasonably assured. Licensing and consulting revenues are generally collected from 30 to 60 days after the invoice is sent. The following table depicts the composition of our accounts receivable as of June 30, 2020, and December 31, 2019: June 30, 2020 December 31, 2019 Accounts receivable – trade $ 1,332,878 $ 384,202 Accounts receivable – related party 124,856 72,658 Accounts receivable – litigation 3,063,968 3,063,968 Allowance for doubtful accounts (41,796 ) (70,885 ) Total accounts receivable $ 4,479,906 $ 3,449,943 The Company establishes an allowance for doubtful accounts based on management’s assessment of the collectability of trade receivables. A considerable amount of judgment is required in assessing the amount of the allowance. The Company makes judgments about the creditworthiness of each customer based on ongoing credit evaluations and monitors current economic trends that might impact the level of credit losses in the future. If the financial condition of the customers were to deteriorate, resulting in their inability to make payments, a specific allowance will be required. At June 30, 2020 and December 31, 2019, the Company recorded an allowance for doubtful accounts of $41,796 and $70,885, respectively. During the six months ended June 30, 2020 and June 30, 2019, the Company recorded a bad debt expense of $29,089 and $0, respectively. |
Notes receivable | Notes Receivable On July 17, 2018, the Company entered into an intellectual property license agreement with Abba Medix Corp. (AMC), a wholly owned subsidiary of publicly traded Canada House Wellness Group, Inc. (CHV). The Company agreed to provide a lending facility to AMC in CAD$125,000 increments of up to CAD$500,000. The lending facility is for a term of 36 months and bears interest at a rate of 2%. As of June 30, 2020 and December 31, 2019, the outstanding balance, including accrued interest, on the notes receivable with AMC totaled $292,101 and $241,711, respectively. The Company classified these loans as noncurrent notes receivable on its consolidated balance sheets as of June 30, 2020 and December 31, 2019, respectively. |
Other assets (current and non-current) | Other Assets (Current and Non-Current) Other assets at June 30, 2020 and December 31, 2019 were $463,879 and $529,416, respectively. As of June 30, 2020, this balance included $422,000 in prepaid expenses and $41,879 in security deposits. At December 31, 2019, other assets included $480,881 in prepaid expenses, $21,085 in interest receivable and $27,450 in security deposits. Prepaid expenses were primarily comprised of insurance premiums, membership dues, conferences and seminars, and other general and administrative costs. |
Goodwill and Intangible Assets | Goodwill and Intangible Assets Goodwill represents the future economic benefit arising from other assets acquired that could not be individually identified and separately recognized. The goodwill arising from the Company’s acquisitions is attributable to the value of the potential expanded market opportunity with new customers. Intangible assets have either an identifiable or indefinite useful life. Intangible assets with identifiable useful lives are amortized on a straight-line basis over their economic or legal life, whichever is shorter. The Company’s amortizable intangible assets consist of licensing agreements, product licenses and registrations, and intellectual property or trade secrets. Their estimated useful lives range from 10 to 15 years. Goodwill and indefinite-lived assets are not amortized but are subject to annual impairment testing unless circumstances dictate more frequent assessments. The Company performs an annual impairment assessment for goodwill during the fourth quarter of each year and more frequently whenever events or changes in circumstances indicate that the fair value of the asset may be less than the carrying amount. Goodwill impairment testing is a two-step process performed at the reporting unit level. Step one compares the fair value of the reporting unit to its carrying amount. The fair value of the reporting unit is determined by considering both the income approach and market approaches. The fair values calculated under the income approach and market approaches are weighted based on circumstances surrounding the reporting unit. Under the income approach, the Company determines fair value based on estimated future cash flows of the reporting unit, which are discounted to the present value using discount factors that consider the timing and risk of cash flows. For the discount rate, the Company relies on the capital asset pricing model approach, which includes an assessment of the risk-free interest rate, the rate of return from publicly traded stocks, the Company’s risk relative to the overall market, the Company’s size and industry and other Company-specific risks. Other significant assumptions used in the income approach include the terminal value, growth rates, future capital expenditures and changes in future working capital requirements. The market approaches use key multiples from guideline businesses that are comparable and are traded on a public market. If the fair value of the reporting unit is greater than its carrying amount, there is no impairment. If the reporting unit’s carrying amount exceeds its fair value, then the second step must be completed to measure the amount of impairment, if any. Step two calculates the implied fair value of goodwill by deducting the fair value of all tangible and intangible net assets of the reporting unit from the fair value of the reporting unit as calculated in step one. In this step, the fair value of the reporting unit is allocated to all of the reporting unit’s assets and liabilities in a hypothetical purchase price allocation as if the reporting unit had been acquired on that date. If the carrying amount of goodwill exceeds the implied fair value of goodwill, an impairment loss is recognized in an amount equal to the excess. Determining the fair value of a reporting unit is judgmental in nature and requires the use of significant estimates and assumptions, including revenue growth rates, strategic plans, and future market conditions, among others. There can be no assurance that the Company’s estimates and assumptions made for purposes of the goodwill impairment testing will prove to be accurate predictions of the future. Changes in assumptions and estimates could cause the Company to perform an impairment test prior to scheduled annual impairment tests. The Company performed its annual fair value assessment at December 31, 2019, on its subsidiaries with material goodwill and intangible asset amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed at June 30, 2020 that would indicate impairment. |
Long-Lived Assets | Long-Lived Assets The Company evaluates the recoverability of its long-lived assets whenever events or changes in circumstances have indicated that an asset may not be recoverable. The long-lived asset is grouped with other assets at the lowest level for which identifiable cash flows are largely independent of the cash flows of other groups of assets and liabilities. If the sum of the projected undiscounted cash flows is less than the carrying value of the assets, the assets are written down to the estimated fair value. The Company evaluated the recoverability of its long-lived assets on December 31, 2019 on its subsidiaries with material amounts on their respective balance sheets and determined that no impairment exists. No additional factors or circumstances existed at June 30, 2020 that would indicate impairment. |
Accounts payable | Accounts Payable Accounts payable at June 30, 2020 and December 31, 2019 were $2,808,718 and $699,961, respectively and were comprised of trade payables for various purchases and services rendered during the ordinary course of business. |
Accrued expenses and other liabilities | Accrued Expenses and Other Liabilities Accrued expenses and other liabilities at June 30, 2020 and December 31, 2019 were $1,848,933 and $1,091,204, respectively. At June 30, 2020, this was comprised of customer deposits of $81,441, accrued payroll of $961,891, and operating expenses of $805,601. At December 31, 2019, accrued expenses and other liabilities was comprised of customer deposits of $148,109, accrued payroll of $714,220, and operating expenses of $228,875. |
Revenue recognition and related allowances | Revenue Recognition and Related Allowances The Company adopted Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606) The Company’s revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. Certain criteria are required to be met in order to recognize revenue. If these criteria are not met, then the associated revenue is deferred until the criteria are met. When consideration is received in advance of the delivery of goods or services, a contract liability is recorded. Revenue contracts are identified when accepted from customers and represent a single performance obligation to sell the Company’s products to a customer. The Company has three main revenue streams: product sales; licensing and consulting fees; and other operating revenues from seminars, reimbursements and other miscellaneous sources. Product sales are recorded at the time that control of the products is transferred to customers. In evaluating the timing of the transfer of control of products to customers, the Company considers several indicators, including significant risks and rewards of products, its right to payment, and the legal title of the products. Based on the assessment of control indicators, sales are generally recognized when products are delivered to customers. Revenue from licensing and consulting services is recognized when the obligations to the client are fulfilled which is determined when milestones in the contract are achieved and target harvest yields are exceeded. At June 30, 2020, all milestones for contracts were satisfactorily reached and no further performance obligations were outstanding on contracts through the period. Revenue from seminar fees is related to one-day seminars and is recognized as earned upon the completion of the seminar. The Company also recognizes expense reimbursement from clients as revenue for expenses incurred during certain jobs. |
Cost of Goods and Services Sold | Costs of Goods and Services Sold Costs of goods and services sold are comprised of related expenses incurred while supporting the implementation and sales of the Company’s products and services. |
General and Administrative Expenses | General and Administrative Expenses General and administrative expense are comprised of all expenses not linked to the production or advertising of the Company’s services. |
Advertising and Marketing Costs | Advertising and Marketing Costs Advertising and marketing costs are expensed as incurred and totaled $336,529 and $465,796 for the three and six months ended June 30, 2020, respectively, as compared to $73,088 and $128,489, respectively, for the three and six months ended June 30, 2019. |
Stock-Based Compensation | Stock Based Compensation Stock compensation expense for stock options is recognized over the vesting period of the award or expensed immediately under ASC 718 and Emerging Issues Task Force (“EITF”) 96-18 when stock or options are awarded for previous or current service without further recourse. Share-based expense paid to through direct stock grants is expensed as occurred. Since the Company’s stock has become publicly traded, the value is determined based on the number of shares issued and the trading value of the stock on the date of the transaction. On June 20, 2018, the FASB issued ASU 2018-07 which simplifies the accounting for share-based payments granted to nonemployees for goods and services. Under the ASU, most of the guidance on such payments to nonemployees would be aligned with the requirements for share-based payments granted to employees. Previously, share-based payment arrangements to nonemployees were accounted for under ASC 718, while nonemployee share-based payments issued for goods and services were accounted for under ASC 505-50. Before the amendment, the major difference for the Company (but not limited to) was the determination of measurement date, which generally is the date on which the measurement of equity classified share-based payments becomes fixed. Equity classified share-based payments for employees was fixed at the time of grant. Equity-classified nonemployee share-based payment awards are no longer measured at the earlier of the date which a commitment for performance by the counterparty is reached or the date at which the counterparty’s performance is complete. They are now measured at the grant date of the award, which is the same as share-based payments for employees. The Company adopted the requirements of the new rule as of January 1, 2019, the effective date of the new guidance. The Company recognized $3,109,091 and $4,361,822 in expense for stock-based compensation from common stock options issued to employees during the three and six months ended June 30, 2020, and $2,225,406 and 2,980,406 in expenses for stock-based compensation from the issuance of common stock to employees, officers, directors and/or contractors during the three and six months ended June 30, 2019. |
Income Taxes | Income Taxes ASC 740, Income Taxes requires the use of the asset and liability method of accounting for income taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. |
Right of Use Assets and Lease Liabilities | Right of Use Assets and Lease Liabilities In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842) Under ASC 842, the Company determines if an arrangement is a lease at inception. ROU assets and liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. As most of the Company's leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in determining the present value of lease payments. The ROU asset also includes any lease payments made prior to commencement and is recorded net of any lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise such options. Operating leases are included in operating lease Right-of-Use assets and operating lease liabilities, current and non-current, on the Company's consolidated balance sheets. |
Basic and Diluted Net Income (Loss) Per Share | Basic and Diluted Net Income (Loss) Per Share The Company computes net income (loss) per share in accordance with ASC 260, “Earnings per Share” |
1. Liquidity and Capital Reso_2
1. Liquidity and Capital Resources (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |
Composition of cash | The following table depicts the composition of the Company’s cash and cash equivalents as of June 30, 2020, and December 31, 2019: June 30, 2020 December 31, 2019 Deposits placed with banks $ 5,418,317 $ 736,101 United States Treasury Bills – 11,117,526 Total cash and cash equivalents $ 5,418,317 $ 11,853,627 |
2. Critical Accounting Polici_3
2. Critical Accounting Policies and Estimates (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Accounting Policies [Abstract] | |
Schedule of fair value measurement | The following is the Company’s assets and liabilities measured at fair value on a recurring and nonrecurring basis at June 30, 2020 and December 31, 2019, using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3): June 30, 2020 December 31, 2019 Level 1 – Marketable Securities Available-for-Sale – Recurring 517,514 406,774 |
Schedule of Accounts Receivable | June 30, 2020 December 31, 2019 Accounts receivable – trade $ 1,332,878 $ 384,202 Accounts receivable – related party 124,856 72,658 Accounts receivable – litigation 3,063,968 3,063,968 Allowance for doubtful accounts (41,796 ) (70,885 ) Total accounts receivable $ 4,479,906 $ 3,449,943 |
4. Property and Equipment (Tabl
4. Property and Equipment (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Property, Plant and Equipment [Abstract] | |
Property and equipment table | Property and equipment are recorded at cost, net of accumulated depreciation and are comprised of the following: June 30, December 31, Furniture and fixtures $ 129,927 $ 98,903 Leasehold improvements 84,679 40,953 Machinery and tools 1,947,949 34,000 Office equipment 75,848 33,833 Software 110,677 – Work in process 884,067 190,743 $ 3,233,147 $ 398,432 Less: Accumulated depreciation (670,535 ) (159,354 ) Total property and equipment, net of depreciation $ 2,562,612 $ 239,078 |
Schedule of property and equipment useful lives | Depreciation on equipment is provided on a straight-line basis over its expected useful lives at the following annual rates. Furniture and fixtures 3 years Leasehold improvements Lesser of the lease term or estimated useful life Machinery and tools 3 years Office equipment 3 years Software 3-5 years |
5. Intangible Asset (Tables)
5. Intangible Asset (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Intangible assets | Intangible assets at June 30, 2020 and December 31, 2019 were comprised of the following: June 30, December 31, License agreement $ 5,300 $ 5,300 Product license and registration 57,300 57,300 Trade secret – intellectual property 32,500 32,500 Subtotal $ 95,100 $ 95,100 Less: accumulated amortization (23,106 ) (19,811 ) Total intangible assets, net of amortization $ 71,994 $ 75,289 |
9. Goodwill (Tables)
9. Goodwill (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Schedule of Goodwill | The following table sets forth the changes in the carrying value of the Company’s goodwill at June 30, 2020 and December 31, 2019: Balance, December 31, 2019 $ 12,304,306 Acquisition of Mesa 5,141,537 Balance, June 30, 2020 $ 17,445,843 |
10. Leases (Tables)
10. Leases (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Balance Sheet Classification Table | Balance Sheet Line June 30, 2020 Asset Operating lease right of use assets Noncurrent assets $ 1,747,109 Liabilities Lease liabilities Noncurrent liabilities $ 1,770,742 |
Operating Lease Costs | The table below summarizes the components of lease costs for the six months ended June 30, 2020. Six Months Ended Operating lease costs $ 101,568 |
Maturities of Lease Liabilities | Maturities of lease liabilities as of June 30, 2020 are as follows: 2020 fiscal year $ 1,793,866 Less: Interest (23,124 ) Present value of lease liabilities $ 1,770,742 |
Future minimum lease obligations | The following table presents the Company’s future minimum lease obligation under ASC 840 as of June 30, 2020: 2020 fiscal year $ 225,732 2021 fiscal year 451,464 2022 fiscal year 451,464 2023 fiscal year 410,232 2024 fiscal year 369,000 2025 fiscal year 123,000 Total $ 2,030,892 |
12. Stockholders' Equity (Table
12. Stockholders' Equity (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Equity [Abstract] | |
Schedule of warrant activity | The following table reflects the change in common stock purchase warrants for the six months ended June 30, 2020. All stock warrants are exercisable for a period of three years from the date of issuance. Number of shares Balance as of January 1, 2020 9,800,000 Warrants exercised – Warrants forfeited – Warrants issued 187,500 Balance as of June 30, 2020 9,987,500 |
13. Segment Information (Tables
13. Segment Information (Tables) | 6 Months Ended |
Jun. 30, 2020 | |
Segment Reporting [Abstract] | |
Schedule of Segment Reporting Information | The following information represents segment activity for the three-month periods ended June 30, 2020 and June 30, 2019: For the Three Months Ended For the Three Months Ended 30-June-2020 30-June-2019 Products Consulting and Licensing Corporate, Infrastructure and Other Total Products Consulting and Licensing Corporate, Infrastructure and Other Total Revenues $ 4,838,654 $ 585,675 $ – $ 5,424,329 $ 1,301,735 $ 456,084 $ – $ 1,757,819 Cost of goods and services $ (2,833,244 ) $ (273,442 ) $ – $ (3,106,686 ) $ (319,229 ) $ (767,184 ) $ – $ (1,086,412 ) Gross profit $ 2,005,410 $ 312,233 $ – $ 2,317,643 $ 982,506 $ (311,100 ) $ – $ 671,406 Intangible assets amortization $ 1,514 $ 133 $ – $ 1,647 $ 1,597 $ 132 $ – $ 1,729 Depreciation $ 79,809 $ 6,701 $ – $ 86,510 $ 1,700 $ 13,266 $ – $ 14,966 Income (loss) from operations $ 925,258 $ 313,028 $ (7,833,993 ) $ (6,595,707 ) $ 237,239 $ (197,465 ) $ (8,862,424 ) $ (8,822,650 ) Segment assets $ 9,578,911 $ (6,240,425 ) $ 2,645,188 $ 5,983,674 $ 222,826 $ (9,269,203 ) $ 12,646,902 $ 3,600,525 The following information represents segment activity for the six-month periods ended June 30, 2020 and June 30, 2019: For the Six Months Ended For the Six Months Ended 30-June-20 30-June-19 Products License/Cons. Corporate Infrastructure and Other Total Products License/Cons. Corporate Infrastructure and Other Total Revenues 7,367,585 1,259,878 – 8,627,463 2,880,042 881,253 – 3,761,295 COGS (4,729,470 ) (525,751 ) – (5,255,221 ) (1,729,670 ) (955,455 ) – (2,685,125 ) Gross profit 2,638,115 734,127 3,372,242 1,150,372 (74,202 ) – 1,076,170 Intangible assets amortization 3,027 268 – 3,295 3,160 265 – 3,425 Depreciation 81,041 9,933 – 90,974 3,400 22,217 – 25,617 Income (loss) from operations 1,371,757 467,455 (9,814,229 ) (7,975,017 ) 179,552 (394,681 ) (11,519,339) (11,734,468 ) Segment assets 22,513,985 247,170 13,251,810 36,012,965 5,435,508 287,359 15,642,009 21,364,876 |
1. Liquidity and Capital Reso_3
1. Liquidity and Capital Resources (Details - Cash) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 | Jun. 30, 2019 | Dec. 31, 2018 |
Total cash and cash equivalents | $ 5,418,317 | $ 11,853,627 | $ 4,347,495 | $ 321,788 |
Bank Deposits [Member] | ||||
Total cash and cash equivalents | 5,418,317 | 736,101 | ||
U S Treasury Bills [Member] | ||||
Total cash and cash equivalents | $ 0 | $ 11,117,526 |
2. Critical Accounting Polici_4
2. Critical Accounting Policies and Estimates (Details - Level 3) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Fair Value Inputs Level 1 [Member] | Fair Value Measurements Recurring [Member] | Marketable Securities [Member] | ||
Fair value assets | $ 517,514 | $ 406,774 |
2. Critical Accounting Polici_5
2. Critical Accounting Policies and Estimates (Details Receivables) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Total accounts receivable | $ 4,479,906 | $ 3,449,943 |
Allowance for doubtful accounts | (41,796) | (70,885) |
Trade Accounts Receivable [Member] | ||
Total accounts receivable | 1,332,878 | 384,202 |
Accounts receivable - related party [Member] | ||
Total accounts receivable | 124,856 | 72,658 |
Accounts receivable - litigation [Member] | ||
Total accounts receivable | $ 3,063,968 | $ 3,063,968 |
2. Critical Accounting Polici_6
2. Critical Accounting Policies and Estimates (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Allowance for doubtful accounts | $ 41,796 | $ 41,796 | $ 70,885 | ||
Debt expense | 29,089 | $ 0 | |||
Notes receivable | 292,101 | 292,101 | 241,711 | ||
Other assets | 463,879 | 463,879 | 529,416 | ||
Intangible assets impairment | 0 | 0 | |||
Accounts payable | 2,808,718 | 2,808,718 | 699,961 | ||
Accrued expenses and other liabilities | 1,848,933 | 1,848,933 | $ 1,091,204 | ||
Advertising and marketing expense | 336,529 | $ 73,088 | 465,796 | 128,489 | |
Stock based compensation expense | $ 3,109,091 | $ 2,225,406 | $ 4,361,822 | $ 2,980,406 | |
Minimum [Member] | |||||
Intangible assets useful lives | 10 years | ||||
Maximum [Member] | |||||
Intangible assets useful lives | 15 years | ||||
CHV [Member] | |||||
Investment shares owned | 17,650,540 | 17,650,540 | 17,650,540 | ||
Accrued Payroll [Member] | |||||
Accrued expenses and other liabilities | $ 961,891 | $ 961,891 | $ 714,220 | ||
Customer Deposits [Member] | |||||
Accrued expenses and other liabilities | 81,441 | 81,441 | 148,109 | ||
Security Deposits [Member] | |||||
Other assets | 41,879 | 41,879 | 27,450 | ||
Operating Expenses [Member] | |||||
Accrued expenses and other liabilities | 805,601 | 805,601 | 228,875 | ||
Prepaid Expenses [Member] | |||||
Other assets | 422,000 | $ 422,000 | 480,881 | ||
Interest Receivable [Member] | |||||
Other assets | 21,085 | ||||
Options [Member] | |||||
Antidilutive shares | 3,474,500 | ||||
Warrants [Member] | |||||
Antidilutive shares | 9,987,500 | ||||
Lending Facility [Member] | AMC [Member] | |||||
Notes receivable | $ 242,959 | $ 242,959 | $ 241,711 |
4. Property and Equipment (Deta
4. Property and Equipment (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Property and Equipment, gross | $ 3,233,147 | $ 398,432 |
Less: Accumulated Depreciation | (670,535) | (159,354) |
Property and equipment, net | 2,562,612 | 239,078 |
Furniture and Fixtures [Member] | ||
Property and Equipment, gross | 129,927 | 98,903 |
Leasehold Improvements [Member] | ||
Property and Equipment, gross | 84,679 | 40,953 |
Machinery and Tools [Member] | ||
Property and Equipment, gross | 1,947,949 | 34,000 |
Office Equipment [Member] | ||
Property and Equipment, gross | 75,848 | 33,833 |
Software [Member] | ||
Property and Equipment, gross | 110,677 | 0 |
Work In Progress [Member] | ||
Property and Equipment, gross | $ 884,067 | $ 190,743 |
4. Property and Equipment (De_2
4. Property and Equipment (Details - Expected life) | 6 Months Ended |
Jun. 30, 2020 | |
Furniture and Fixtures [Member] | |
Estimated useful life | 3 years |
Leasehold Improvements [Member] | |
Estimated useful life | Lesser of the lease term or estimated useful life |
Machinery and Tools [Member] | |
Estimated useful life | 3 years |
Office Equipment [Member] | |
Estimated useful life | 3 years |
Software [Member] | |
Estimated useful life | 3-5 years |
4. Property and Equipment (De_3
4. Property and Equipment (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Property, Plant and Equipment [Abstract] | ||||
Depreciation expense | $ 86,510 | $ 14,966 | $ 90,974 | $ 25,617 |
5. Intangible Asset (Details)
5. Intangible Asset (Details) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Intangible assets, gross | $ 95,100 | $ 95,100 |
Less: accumulated amortization | (23,106) | (19,811) |
Intangible assets, net | 71,994 | 75,289 |
Trade Secret [Member] | ||
Intangible assets, gross | 32,500 | 32,500 |
Product License and Registration [Member] | ||
Intangible assets, gross | 57,300 | 57,300 |
License Agreement [Member] | ||
Intangible assets, gross | $ 5,300 | $ 5,300 |
5. Intangible Asset (Details Na
5. Intangible Asset (Details Narrative) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | |
Goodwill and Intangible Assets Disclosure [Abstract] | ||||
Amortization expense | $ 1,647 | $ 1,729 | $ 3,295 | $ 3,425 |
6. Derivative Liability (Detail
6. Derivative Liability (Details Narrative) - USD ($) | Jan. 08, 2019 | Feb. 25, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | Apr. 23, 2019 | Jun. 11, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 |
Fair value of derivative liabilities | $ 1,467,318 | $ 1,467,318 | $ 3,773,382 | ||||||
Change in fair value of derivatives | (348,535) | $ 80,472 | 843,428 | $ (254,564) | |||||
Gain on forfeiture of contingent consideration | $ 0 | $ 0 | $ 1,462,636 | $ 0 | |||||
Officer [Member] | |||||||||
Restricted stock granted, shares | 500,000 | 1,000,000 | 1,000,000 | ||||||
Gain on forfeiture of contingent consideration | $ 1,462,636 |
7. Related Party Transactions (
7. Related Party Transactions (Details Narrative) - USD ($) | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Notes receivable issued | $ 50,390 | $ 229,358 | |
Med Man Denver [Member] | |||
Revenue from related parties | 170,106 | ||
Accounts receivable from related parties | 83,679 | ||
Med Pharm Holdings [Member] | |||
Revenue from related parties | $ 0 | ||
Accounts receivable from related parties | 3,326 | ||
Notes receivable issued | $ 767,695 | ||
Note receivable interest rate | 8-10% | ||
Note receivable maturity date | July 2020 | ||
Baseball 18 LLC [Member] | |||
Revenue from related parties | 0 | ||
Accounts payable from related party | 156,318 | ||
Farm Boy [Member] | |||
Revenue from related parties | 0 | ||
Accounts payable from related party | 245,953 | ||
Emerald Fields [Member] | |||
Revenue from related parties | 0 | ||
Accounts payable from related party | 114,838 | ||
Los Suenos [Member] | |||
Revenue from related parties | 0 | ||
Accounts payable from related party | $ 51,237 |
8. Inventory (Details Narrative
8. Inventory (Details Narrative) - USD ($) | 6 Months Ended | ||
Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Inventory Disclosure [Abstract] | |||
Inventory | $ 1,977,572 | $ 684,940 | |
Finished goods inventory | 849,153 | ||
Raw materials inventory | 1,128,419 | ||
Inventory obsolescence | $ 0 | $ 0 |
9. Goodwill (Details)
9. Goodwill (Details) | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Goodwill and Intangible Assets Disclosure [Abstract] | |
Balance at beginning | $ 12,304,306 |
Acquisition of Mesa | 5,141,537 |
Balance at end | $ 17,445,843 |
9. Goodwill (Details Narrative)
9. Goodwill (Details Narrative) - USD ($) | 4 Months Ended | 6 Months Ended | |
Apr. 20, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | |
Goodwill acquired | $ 5,141,537 | ||
Cash to be paid for acquisition | $ 2,609,500 | $ 0 | |
Mesa Organics [Member] | |||
Goodwill acquired | $ 5,141,537 | ||
Cash to be paid for acquisition | $ 2,609,500 | ||
Stock issued for acquisition, shares | 2,554,750 | ||
Common stock par value | $ 0.001 |
10. Leases (Details - Balance S
10. Leases (Details - Balance Sheet Classification) - USD ($) | Jun. 30, 2020 | Dec. 31, 2019 |
Leases [Abstract] | ||
Operating lease asset - non-current | $ 1,747,109 | $ 59,943 |
Operating lease liability - non-current | $ 1,770,742 | $ 66,803 |
10. Leases (Details - Operating
10. Leases (Details - Operating lease cost) | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Leases [Abstract] | |
Operating lease costs | $ 101,568 |
10. Leases (Details - Lease mat
10. Leases (Details - Lease maturities) | Jun. 30, 2020USD ($) |
Leases [Abstract] | |
2020 fiscal year | $ 1,793,866 |
Less: interest | (23,124) |
Present value of lease liabilities | $ 1,770,742 |
10. Leases (Details - Minimum l
10. Leases (Details - Minimum lease obligation) | Jun. 30, 2020USD ($) |
Leases [Abstract] | |
2020 fiscal year | $ 225,732 |
2021 fiscal year | 451,464 |
2022 fiscal year | 451,464 |
2023 fiscal year | 410,232 |
2024 fiscal year | 369,000 |
2025 fiscal year | 123,000 |
Total | $ 2,030,892 |
10. Leases (Details Narrative)
10. Leases (Details Narrative) | 6 Months Ended |
Jun. 30, 2020 | |
Leases [Abstract] | |
Weighted average remaining lease term | 3-5 years |
Weighted average lease discount rate | 6.00% |
11. Commitments and Contingen_2
11. Commitments and Contingencies (Details Narrative) - USD ($) | 5 Months Ended | 6 Months Ended | 7 Months Ended | 8 Months Ended | ||
Jun. 05, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | Aug. 15, 2019 | Sep. 09, 2019 | Sep. 05, 2019 | |
Cash to be paid for acquisition | $ 2,609,500 | $ 0 | ||||
Medically Correct [Member] | ||||||
Consideration to be transferred | $ 17,250,000 | |||||
Cash to be paid for acquisition | $ 3,450,000 | |||||
Stock to be issued for acquisition | 4,677,967 | |||||
Roots RX [Member] | ||||||
Consideration to be transferred | $ 15,000,000 | |||||
Cash to be paid for acquisition | $ 9,750,000 | |||||
Stock to be issued for acquisition | 1,779,661 | |||||
Canyon [Member] | ||||||
Consideration to be transferred | $ 5,130,000 | |||||
Cash to be paid for acquisition | $ 2,565,000 | |||||
Starbuds [Member] | ||||||
Consideration to be transferred | $ 118,000,000 |
12. Stockholders' Equity (Detai
12. Stockholders' Equity (Details Warrant Activity) - Warrants [Member] | 6 Months Ended |
Jun. 30, 2020shares | |
Warrants outstanding, beginning balance | 9,800,000 |
Warrants exercised | 0 |
Warrants forfeited | 0 |
Warrants issued | 187,500 |
Warrants outstanding, ending balance | 9,987,500 |
12. Stockholders' Equity (Det_2
12. Stockholders' Equity (Details Narrative) - USD ($) | Jan. 08, 2019 | Mar. 14, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Apr. 20, 2020 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 |
Common stock authorized | 90,000,000 | 90,000,000 | 90,000,000 | |||||
Common stock par value | $ 0.001 | $ 0.001 | $ 0.001 | |||||
Common stock issued | 42,194,878 | 42,194,878 | 39,952,628 | |||||
Common stock outstanding | 41,937,146 | 41,937,146 | 39,952,628 | |||||
Proceeds from warrant exercises | $ 0 | $ 601,725 | ||||||
Stock issued for services, value | $ 305,522 | $ 305,522 | ||||||
Stock issued for acquisition , value | $ 4,169,808 | $ 4,169,808 | ||||||
Warrant Exercises [Member] | ||||||||
Issuance of common stock in connection with the exercise of common stock purchase warrants, shares | 452,426 | 187,500 | ||||||
Proceeds from warrant exercises | $ 0 | $ 601,725 | ||||||
James Toreson [Member] | Consulting Agreement [Member] | ||||||||
Stock issued for services, shares | 50,000 | |||||||
Stock issued for services, value | $ 95,000 | |||||||
Accredited Investors [Member] | ||||||||
Warrants issued, shares | 9,800,000 | |||||||
Warrant term | 3 years | |||||||
Warrant exercisable price | $ 3.50 | |||||||
Mesa Organics [Member] | ||||||||
Stock issued for acquisition, shares | 2,554,750 | |||||||
Stock issued for acquisition , value | $ 4,167,253 | |||||||
Paul Dickman [Member] | ||||||||
Stock issued for services, shares | 500,000 | |||||||
Stock issued for services, value | $ 660,000 |
13. Segment Information (Detail
13. Segment Information (Details- Segment Information) - USD ($) | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2020 | Jun. 30, 2019 | Jun. 30, 2020 | Jun. 30, 2019 | Dec. 31, 2019 | |
Revenues | $ 5,424,329 | $ 1,757,819 | $ 8,627,463 | $ 3,761,295 | |
Cost of goods and services | (3,106,686) | (1,086,413) | (5,255,221) | (2,685,125) | |
Gross profit | 2,317,643 | 671,406 | 3,372,242 | 1,076,170 | |
Intangible assets amortization | 1,647 | 1,729 | 3,295 | 3,425 | |
Depreciation | 86,510 | 14,966 | 90,974 | 25,617 | |
Net income (loss) | (6,595,707) | (8,822,650) | (7,975,017) | (11,734,468) | |
Segment assets | 36,012,965 | 21,364,876 | 36,012,965 | 21,364,876 | $ 32,228,607 |
Products [Member] | |||||
Revenues | 4,838,654 | 1,301,735 | 7,367,585 | 2,880,042 | |
Cost of goods and services | (2,833,244) | (319,229) | (4,729,470) | (1,729,670) | |
Gross profit | 2,005,410 | 982,506 | 2,638,115 | 1,150,372 | |
Intangible assets amortization | 1,514 | 1,597 | 3,027 | 3,160 | |
Depreciation | 79,809 | 1,700 | 81,041 | 3,400 | |
Net income (loss) | 925,258 | 237,239 | 1,371,757 | 179,552 | |
Segment assets | 22,513,985 | 5,435,508 | 22,513,985 | 5,435,508 | |
Licensing and Consulting [Member] | |||||
Revenues | 585,675 | 456,084 | 1,259,878 | 881,253 | |
Cost of goods and services | (273,442) | (767,184) | (525,751) | (955,455) | |
Gross profit | 312,233 | (311,100) | 734,127 | (74,202) | |
Intangible assets amortization | 133 | 132 | 268 | 265 | |
Depreciation | 6,701 | 13,266 | 9,933 | 22,217 | |
Net income (loss) | 313,028 | (197,465) | 467,455 | (394,681) | |
Segment assets | 247,170 | 287,359 | 247,170 | 287,359 | |
Corporate, Infrastructure and Other [Member] | |||||
Revenues | 0 | 0 | 0 | ||
Cost of goods and services | 0 | 0 | 0 | ||
Gross profit | 0 | 0 | 0 | ||
Intangible assets amortization | 0 | 0 | 0 | ||
Depreciation | 0 | 0 | 0 | ||
Net income (loss) | (7,833,993) | (8,862,424) | (9,814,229) | (11,519,339) | |
Segment assets | $ 13,251,810 | $ 15,642,009 | $ 13,251,810 | $ 15,642,009 |
14. Tax Provision (Details Narr
14. Tax Provision (Details Narrative) | 6 Months Ended |
Jun. 30, 2020USD ($) | |
Income Tax Disclosure [Abstract] | |
Net operating loss carryover | $ 10,200,000 |
NOL beginning expiration date | Dec. 31, 2039 |